Abstract 060: Adipose Derived Stem Cell (ADSC) Therapy Prevents The Progression Of Hypertension And Improves Cardiac Functions
Despite major advances in pharmacological and interventional therapies, 30% of hypertensive patients do not achieve their blood pressure (BP) target and have apparent treatment resistant hypertension (TRH). Thus, innovative strategies are urgently needed for the control of TRH considering its prevalence and deleterious complications. The objective of the current study was to evaluate effects of ADSC on BP in spontaneously hypertensive rats (SHR). The rational for using ADSC is that they have multipotent differentiation capacities and potent anti-inflammatory effects. Moreover, autologous ADSC are an attractive therapeutic option for clinical trials based on availability, less invasive isolation procedure, and safety in several hundred patient studies. ADSC were isolated from inguinal adipose tissue of a normotensive WKY rat, characterized using flow cytometry (CD44+,CD90+,CD34- and CD45-), and their differentiation ability to adipocyte was confirmed by Oil Red “O” staining. Basal systolic BP for SHR at 13 week age was 191.6 ± 5.6 mmHg measured by a tail-cuff method. SHR animals were then randomly assigned to control and ADSC-treated groups. ADSC (5х106 cells/animal) was intravenously administered through jugular vein into treated SHR. Three weeks after treatment, left ventricular function was assessed using echocardiography and direct BP was measured using a Millar catheter. The SHR control exhibited 82% increase in systolic BP (198.4 ± 25.9 vs WKY: 109.0 ± 1.6, mmHg) and 14% elevation in ventricular mass (3.3 ± 0.2 vs WKY: 2.9 ± 0.1, g/kg). Furthermore, the SHR control demonstrated 42% increase in deceleration time of mitral valve (58.1 ± 6.0 vs WKY: 40.8 ± 2.3; ms) and 21% decrease in ejection fraction (69.9 ± 4.2 vs WKY: 88.2 ± 1.3, %). Single injection of ADSC resulted in a 28% decrease in systolic BP (142.5 ± 25.8mmHg), 18% reduction in ventricular mass (2.7 ± 0.3g/kg), 36% decrease in deceleration time of mitral valve (36.9 ± 16.3ms), and 17% increase in ejection fraction (80.0 ± 3.4%). Collectively, our data demonstrate that ADSC arrested the progression of hypertension and associated left ventricular dysfunction in the hypertensive animals. It warrants additional study on ADSC intervention as a potential alternative treatment for hypertension.
Author Disclosures: Y. Qi: None. A. Rathinasabapathy: None. J. Zhang: None. M. Zingler: None. F. Wong: None. J.W. Petersen: None. M.J. Katovich: None. M.K. Raizada: None. C.J. Pepine: None.
- © 2014 by American Heart Association, Inc.